Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519514 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL4519164 | 0.99 | KDM4E (0.45) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL4510224 | 0.99 | KDM4E (0.46) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL4528287 | 0.97 | KDM4E (0.46) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL4523167 | 0.93 | MCL1 (0.51) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL4520480 | 0.92 | TLR9 (0.43) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL4530946 | 0.92 | MCL1 (0.49) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL4529531 | 0.91 | KDM4E (0.45) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL4505975 | 0.91 | KDM4E (0.45) | KDM4EALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL4505463 | 0.91 | MAPT (0.45) | KDM4EALDH1A1KMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | claimed |
| EP-1841755-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2007-10-10 | — | — | EP | claimed |
| WO-2006070001-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2006-07-06 | — | — | WO | claimed |
| EP-1676843-A1 | Substituted indole ligands for the ORL-1 receptor | NIKEM RESEARCH S.R.L. (IT) | 2006-07-05 | — | — | EP | claimed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| EP-1841755-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006070001-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676843-A1 | Substituted indole ligands for the ORL-1 receptor | NIKEM RESEARCH S.R.L. (IT) | 2006-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | KDM4E 4525/4885ALDH1A1 395/4885KMT2A 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.